Immunotherapy of B-cell malignancies using anti-CD22 antibodies
First Claim
1. A method for treating a B-cell malignance, comprising the step of administering to a subject having a B-cell related malignancy a therapeutic composition comprising a pharmaceutically acceptable carrier and a combination of at least one naked anti-CD19 antibody and an anfi-CD20 antibody.
1 Assignment
0 Petitions
Accused Products
Abstract
B-cell malignancies, such as the B-cell subtype of non-Hodgkin'"'"'s lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
545 Citations
33 Claims
- 1. A method for treating a B-cell malignance, comprising the step of administering to a subject having a B-cell related malignancy a therapeutic composition comprising a pharmaceutically acceptable carrier and a combination of at least one naked anti-CD19 antibody and an anfi-CD20 antibody.
- 5. A method for treating a B-cell malignancy, comprising administering to a human subject having a B-cell malignancy a therapeutic composition consisting essentially of a pharmaceutically acceptable carrier and at least one naked anti-CD22 antibody, administered parenterally in a dose of from 20 to 1500 mg per dose.
- 9. A method for treating a B-cell malinanc, comprising administering parenterally to a subject having a B-cell malignincy a therapeutic composition comprising a combination of at least one naked anti-CD22 antibody and an anti-CD19 antibody, a combination of at least one naked anti-CD22 antibody and an anti-CD20 antibody, or a combination of at least one naked anti-CD22 antibody, an anti-CD19 antibody and an anti-CD20 antibody, in a pharmaceutically acceptable carrier. wherein the dosage of said anti-CD22 antibody is from 20 to 1500 mg per dose.
Specification